Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis

Key points

Reviews the latest advances pertaining to the complex genetics, pathophysiology, therapeutic development, and exposome science of ALS.

Screenshot of the first two pages of the paper

Affiliates

Stephen A Goutman [1], Orla Hardiman [2], Ammar Al-Chalabi [3], Adriano Chió [4], Masha G Savelieff [1], Matthew C Kiernan [5], Eva L Feldman [6]

  1. Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  2. Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  3. Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, and Department of Neurology, King's College London, London, UK.
  4. Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy.
  5. Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  6. Department of Neurology, University of Michigan, Ann Arbor, MI, USA

Journal

The Lancet

Summary

This research paper highlights the latest advances from the past 5 years pertaining to the complex genetics, pathophysiology, therapeutic development, and exposome science of amyotrophic lateral sclerosis. With the advances in genetic research and therapies, the paper suggests the future direction of applying gene profiling and genetic therapies to new clinical trials for ALS.

Link to Paper

Read the paper here!

Print
Content Source:
Agency for Toxic Substances and Disease Registry